J&J Beats With $25.4B Q3 Revenue, Raises FY Outlook and Plans DePuy Synthes Spin-Off
JNJ sits 37% above its 52-week low of $184.66.
Summary
J&J reported Q3 revenue of $25.4B, up 6% year over year, with adjusted EPS of $2.59, and lifted full-year guidance to roughly $101.2B in sales and $11.10 in adjusted EPS. Pharma carried the quarter at $16.76B: Tremfya jumped 68% to $2.4B and Darzalex rose 16% to $4.24B, while Stelara fell 54% to $716M as biosimilar competition bites. MedTech added $8.6B, helped by the newly cleared OTTAVA surgical robot. Management also confirmed it will spin off the DePuy Synthes orthopedics business into a standalone company by mid-2027, with details and 2027 guidance at a December 8 investor event. The raise comes despite the proposed $5.5B ovarian talc settlement and the earlier Firefly Bio and Sail Biomedicines deals that had trimmed 2026 EPS guidance in July. The Dec. 8 event is the next hard date for spin-off structure and 2027 targets.
At the time of this announcement, JNJ was trading at $253.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $615.9B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.